432 related articles for article (PubMed ID: 23862748)
41. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
[TBL] [Abstract][Full Text] [Related]
42. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma.
Fan Q; He M; Deng X; Wu WK; Zhao L; Tang J; Wen G; Sun X; Liu Y
Cell Biochem Funct; 2013 Jun; 31(4):319-24. PubMed ID: 23001723
[TBL] [Abstract][Full Text] [Related]
43. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
Wei W; Hu Z; Fu H; Tie Y; Zhang H; Wu Y; Zheng X
Oncol Rep; 2012 Aug; 28(2):701-6. PubMed ID: 22664953
[TBL] [Abstract][Full Text] [Related]
45. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
Shi Y; Huang A
Tumour Biol; 2015 Nov; 36(11):8455-63. PubMed ID: 26026584
[TBL] [Abstract][Full Text] [Related]
46. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients.
Wang C; Song B; Song W; Liu J; Sun A; Wu D; Yu H; Lian J; Chen L; Han J
J Gastroenterol Hepatol; 2011 Nov; 26(11):1630-7. PubMed ID: 21557766
[TBL] [Abstract][Full Text] [Related]
47. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M
Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846
[TBL] [Abstract][Full Text] [Related]
48. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
49. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.
He XX; Chang Y; Meng FY; Wang MY; Xie QH; Tang F; Li PY; Song YH; Lin JS
Oncogene; 2012 Jul; 31(28):3357-69. PubMed ID: 22056881
[TBL] [Abstract][Full Text] [Related]
50. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.
Ren FH; Yang H; He RQ; Lu JN; Lin XG; Liang HW; Dang YW; Feng ZB; Chen G; Luo DZ
BMC Cancer; 2018 Jan; 18(1):12. PubMed ID: 29298665
[TBL] [Abstract][Full Text] [Related]
51. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
52. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.
Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026
[TBL] [Abstract][Full Text] [Related]
54. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.
Wei C; Luo Q; Sun X; Li D; Song H; Li X; Song J; Hua K; Fang L
Int J Clin Exp Pathol; 2015; 8(7):7729-39. PubMed ID: 26339338
[TBL] [Abstract][Full Text] [Related]
56. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
57. MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor γ.
Li S; Li J; Fei BY; Shao D; Pan Y; Mo ZH; Sun BZ; Zhang D; Zheng X; Zhang M; Zhang XW; Chen L
Chin Med J (Engl); 2015 Apr; 128(7):941-7. PubMed ID: 25836616
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
59. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling.
Wang Y; Hu C; Cheng J; Chen B; Ke Q; Lv Z; Wu J; Zhou Y
Biochem Biophys Res Commun; 2014 Apr; 446(4):1255-60. PubMed ID: 24690171
[TBL] [Abstract][Full Text] [Related]
60. Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus.
Yeh TS; Wang F; Chen TC; Yeh CN; Yu MC; Jan YY; Chen MF
Ann Surg; 2014 Feb; 259(2):346-54. PubMed ID: 24135722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
